BMY Q3 2019 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$121B

Q3 2019 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$6.0B+5.6% YoY

Gross Profit

$4.2B70.2% margin

Operating Income

$1.8B30.0% margin

Net Income

$1.4B22.5% margin

EPS (Diluted)

$0.83

QoQ Revenue Growth

-4.2%

Cash Flow

Operating Cash Flow

$2.6B

Free Cash Flow

$2.4B

Stock-Based Comp.

$56M

Balance Sheet

Total Assets

$57.4B

Total Liabilities

$39.7B

Stockholders' Equity

$17.6B

Cash & Equivalents

$30.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6.0B	$5.7B	+5.6%
Gross Profit	$4.2B	$4.0B	+4.4%
Operating Income	$1.8B	$1.7B	+7.5%
Net Income	$1.4B	$1.9B	-28.8%

Revenue Segments

Eliquis

$1.9B32%

Opdivo

$1.8B30%

Orencia

$767M13%

Sprycel

$558M9%

Yervoy

$353M6%

Mature Products And All Other

$350M6%

Baraclude

$145M2%

Empliciti

$89M1%

Geographic Segments

UNITED STATES

$3.5B58%

Europe

$1.4B24%

Rest Of World

$976M16%

Other Region

$114M2%